Frederick L. Locke, MD, is chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy, and a medical oncologist and translational researcher who treats lymphoma and multiple myeloma at Moffitt Cancer Center in Tampa, Florida. He also conducts clinical trials of CAR T-cell therapy for patients with lymphoma and myeloma.
Allogeneic vs Autologous CAR T-Cell Therapy Explained
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.